دورية أكاديمية
أعرض في EDS

Modulating the expression of tumor suppressor genes using activating oligonucleotide technologies as a therapeutic approach in cancer.

التفاصيل البيبلوغرافية
العنوان: Modulating the expression of tumor suppressor genes using activating oligonucleotide technologies as a therapeutic approach in cancer.
المؤلفون: Gregory GL; Department of Pharmacology & Therapeutics, Institute of Systems, Molecular & Integrative Biology, University of Liverpool, Liverpool L69 3GE, UK., Copple IM; Department of Pharmacology & Therapeutics, Institute of Systems, Molecular & Integrative Biology, University of Liverpool, Liverpool L69 3GE, UK.
المصدر: Molecular therapy. Nucleic acids [Mol Ther Nucleic Acids] 2022 Dec 27; Vol. 31, pp. 211-223. Date of Electronic Publication: 2022 Dec 27 (Print Publication: 2023).
نوع المنشور: Journal Article; Review
اللغة: English
بيانات الدورية: Publisher: Cell Press Country of Publication: United States NLM ID: 101581621 Publication Model: eCollection Cited Medium: Print ISSN: 2162-2531 (Print) Linking ISSN: 21622531 NLM ISO Abbreviation: Mol Ther Nucleic Acids Subsets: PubMed not MEDLINE
أسماء مطبوعة: Publication: 2017- : Cambridge, MA : Cell Press
Original Publication: New York, NY : Nature Pub. Group
مستخلص: Tumor suppressor genes (TSGs) are frequently downregulated in cancer, leading to dysregulation of the pathways that they control. The continuum model of tumor suppression suggests that even subtle changes in TSG expression, for example, driven by epigenetic modifications or copy number alterations, can lead to a loss of gene function and a phenotypic effect. This approach to exploring tumor suppression provides opportunities for alternative therapies that may be able to restore TSG expression toward normal levels, such as oligonucleotide therapies. Oligonucleotide therapies involve the administration of exogenous nucleic acids to modulate the expression of specific endogenous genes. This review focuses on two types of activating oligonucleotide therapies, small-activating RNAs and synthetic mRNAs, as novel methods to increase the expression of TSGs in cancer.
Competing Interests: G.G.’s PhD studentship is supported through in-kind contributions from MiNA Therapeutics. The company has not been involved in the preparation of this manuscript.
(© 2023 The Authors.)
References: Acta Pharmacol Sin. 2011 Jul;32(7):939-46. (PMID: 21666704)
J Clin Oncol. 2021 May 10;39(14):1584-1594. (PMID: 33449813)
J Exp Clin Cancer Res. 2016 Mar 25;35:53. (PMID: 27012825)
Cancer Sci. 2010 Aug;101(8):1790-6. (PMID: 20518789)
Immunity. 2005 Aug;23(2):165-75. (PMID: 16111635)
N Engl J Med. 2008 Jul 24;359(4):378-90. (PMID: 18650514)
Oncol Rep. 2016 Apr;35(4):2487-93. (PMID: 26797252)
Int J Clin Exp Pathol. 2018 Dec 01;11(12):5792-5800. (PMID: 31949665)
Int J Biochem Cell Biol. 2018 Apr;97:36-42. (PMID: 29425832)
Mol Ther. 2008 Nov;16(11):1833-40. (PMID: 18797453)
Cancer Res. 2010 Dec 15;70(24):10182-91. (PMID: 21159640)
Mol Ther Nucleic Acids. 2019 Dec 6;18:142-154. (PMID: 31546149)
Am J Transl Res. 2020 Aug 15;12(8):4175-4188. (PMID: 32913496)
Curr Pharm Biotechnol. 2018;19(8):611-621. (PMID: 29886828)
J Gene Med. 2013 Nov-Dec;15(11-12):414-26. (PMID: 24123772)
Proc Natl Acad Sci U S A. 1999 Dec 7;96(25):14476-81. (PMID: 10588730)
N Engl J Med. 2020 Oct 15;383(16):1544-1555. (PMID: 32722908)
Clin Cancer Res. 2020 Dec 1;26(23):6284-6298. (PMID: 32817076)
J Exp Clin Cancer Res. 2016 Sep 17;35(1):145. (PMID: 27639690)
Nature. 2011 Aug 10;476(7359):163-9. (PMID: 21833082)
Adv Exp Med Biol. 2017;983:217-229. (PMID: 28639203)
Biochem Biophys Res Commun. 2017 Jan 22;482(4):542-548. (PMID: 27856244)
Cell. 2011 Mar 4;144(5):646-74. (PMID: 21376230)
PLoS Biol. 2003 Dec;1(3):E59. (PMID: 14691534)
Dev Cell. 2009 Jul;17(1):9-26. (PMID: 19619488)
Cell. 1996 Jul 12;86(1):147-57. (PMID: 8689682)
Cell. 1976 Dec;9(4 PT 2):645-53. (PMID: 1017010)
Proc Natl Acad Sci U S A. 2008 Jul 29;105(30):10360-5. (PMID: 18650397)
Int J Clin Exp Pathol. 2020 Jun 01;13(6):1372-1380. (PMID: 32661472)
Adv Exp Med Biol. 2017;983:173-188. (PMID: 28639199)
N Engl J Med. 2020 Nov 12;383(20):1920-1931. (PMID: 32663912)
Gene. 2013 Sep 15;527(1):102-8. (PMID: 23769968)
Oncotarget. 2017 Apr 11;8(15):25055-25065. (PMID: 28445988)
Signal Transduct Target Ther. 2021 Feb 8;6(1):53. (PMID: 33558455)
Cell Cycle. 2018;17(13):1602-1613. (PMID: 29895194)
Clin Cancer Res. 2021 Nov 1;27(21):5961-5978. (PMID: 34407972)
J Biol Chem. 2004 Mar 26;279(13):12542-50. (PMID: 14729660)
Mol Ther. 2019 Apr 10;27(4):794-802. (PMID: 30655211)
Sci Transl Med. 2021 Jun 23;13(599):. (PMID: 34162754)
Nat Biotechnol. 2011 Feb;29(2):154-7. (PMID: 21217696)
J Cancer Res Clin Oncol. 2009 Feb;135(2):241-7. (PMID: 18663475)
Nat Rev Drug Discov. 2014 Oct;13(10):759-80. (PMID: 25233993)
Nat Biomed Eng. 2018 Nov;2(11):850-864. (PMID: 31015614)
Proc Natl Acad Sci U S A. 2006 Nov 14;103(46):17337-42. (PMID: 17085592)
N Engl J Med. 2020 Jun 11;382(24):2289-2301. (PMID: 32521132)
Cancer Cell. 2012 May 15;21(5):614-625. (PMID: 22624712)
Mol Ther. 2018 Aug 1;26(8):2034-2046. (PMID: 29910178)
Oncol Rep. 2017 Nov;38(5):3160-3166. (PMID: 29048679)
Proc Natl Acad Sci U S A. 1971 Apr;68(4):820-3. (PMID: 5279523)
J Am Chem Soc. 2014 Dec 10;136(49):16958-61. (PMID: 25434769)
J Control Release. 2015 Nov 10;217:345-51. (PMID: 26264835)
Mol Ther Nucleic Acids. 2018 Sep 7;12:845-853. (PMID: 30161023)
Hepatology. 2014 Jan;59(1):216-27. (PMID: 23929703)
Nat Genet. 2010 May;42(5):454-8. (PMID: 20400965)
Oncotarget. 2016 Apr 19;7(16):22893-910. (PMID: 27014974)
Int J Oncol. 2018 Jun;52(6):1815-1826. (PMID: 29620261)
Oncogene. 2018 Jun;37(24):3216-3228. (PMID: 29511346)
Sci Transl Med. 2019 Jan 30;11(477):. (PMID: 30700577)
Mol Ther. 2020 Mar 4;28(3):709-722. (PMID: 31968213)
Nucleic Acids Res. 2016 Aug 19;44(14):6518-48. (PMID: 27084936)
Cell Res. 2016 Mar;26(3):320-35. (PMID: 26902284)
Adv Sci (Weinh). 2022 Sep;9(26):e2200562. (PMID: 35712764)
Prostate. 2013 Oct;73(14):1591-601. (PMID: 23836514)
Nucleic Acids Res. 2017 Dec 1;45(21):12388-12400. (PMID: 29069408)
Nat Rev Drug Discov. 2020 Jul;19(7):441-442. (PMID: 32341501)
Mol Ther Nucleic Acids. 2012 Mar 27;1:e15. (PMID: 23343884)
Int J Cancer. 2009 Jul 15;125(2):446-52. (PMID: 19384944)
J Gene Med. 2008 Aug;10(8):910-7. (PMID: 18563851)
N Engl J Med. 2003 Mar 13;348(11):994-1004. (PMID: 12637609)
Proc Natl Acad Sci U S A. 2010 Aug 3;107(31):13824-9. (PMID: 20631300)
Comput Biol Chem. 2019 Jun;80:398-408. (PMID: 31128451)
Thorac Cancer. 2016 Jul;7(4):481-5. (PMID: 27385992)
Nat Rev Drug Discov. 2020 Oct;19(10):673-694. (PMID: 32782413)
Cancer Cell. 2009 May 5;15(5):376-88. (PMID: 19411067)
Nucleic Acids Res. 2010 Nov;38(21):7736-48. (PMID: 20675357)
Cell Biol Int. 2018 Apr;42(4):495-503. (PMID: 29274293)
Nucleic Acid Ther. 2012 Oct;22(5):335-43. (PMID: 22909100)
Biochem Biophys Res Commun. 2008 Oct 31;375(4):566-70. (PMID: 18725195)
Cell Death Dis. 2018 Apr 18;9(5):439. (PMID: 29670092)
Hum Gene Ther. 2006 Mar;17(3):253-63. (PMID: 16544975)
Clin Cancer Res. 2020 Aug 1;26(15):3936-3946. (PMID: 32357963)
World J Surg Oncol. 2012 Jan 13;10:11. (PMID: 22244202)
Nucleic Acids Res. 2016 Mar 18;44(5):2274-82. (PMID: 26873922)
PLoS One. 2016 Apr 06;11(4):e0153117. (PMID: 27050434)
Nat Chem Biol. 2007 Mar;3(3):166-73. (PMID: 17259978)
Proc Natl Acad Sci U S A. 1989 Aug;86(16):6077-81. (PMID: 2762315)
Mol Cancer Ther. 2008 Mar;7(3):698-703. (PMID: 18347154)
J Clin Oncol. 2012 Oct 10;30(29):3633-9. (PMID: 22965953)
Nat Commun. 2021 Jan 27;12(1):613. (PMID: 33504774)
Cell. 2009 Feb 6;136(3):496-507. (PMID: 19167051)
Int J Oncol. 2016 Oct;49(4):1620-8. (PMID: 27498620)
N Engl J Med. 2020 Dec 31;383(27):2603-2615. (PMID: 33301246)
Nat Commun. 2017 Mar 02;8:14630. (PMID: 28251988)
Nature. 1987 Sep 24-30;329(6137):341-3. (PMID: 3498123)
Biochem J. 2009 May 27;420(3):421-8. (PMID: 19309309)
Int J Oncol. 2016 Mar;48(3):869-85. (PMID: 26698230)
EMBO J. 1989 Jun;8(6):1711-7. (PMID: 2788574)
Blood Cancer J. 2016 Jul 15;6(7):e447. (PMID: 27421096)
فهرسة مساهمة: Keywords: MT: oligonucleotides: therapies and applications; cancer; mRNA; oligonucleotide; saRNA; tumor suppressor gene
تواريخ الأحداث: Date Created: 20230126 Latest Revision: 20230202
رمز التحديث: 20240628
مُعرف محوري في PubMed: PMC9840112
DOI: 10.1016/j.omtn.2022.12.016
PMID: 36700046
قاعدة البيانات: MEDLINE
الوصف
تدمد:2162-2531
DOI:10.1016/j.omtn.2022.12.016